Therapeutic in vivo selection of thymic-derived natural T regulatory cells following non-myeloablative hematopoietic stem cell transplant for IPEX

Clinical Immunology

Volumn 141, Issue 2, 2011, Pages 169-176

  Kasow, Kimberly A ^a,b   Morales Tirado, Vanessa M ^a   Wichlan, David ^a   Shurtleff, Sheila A ^a   Abraham, Allistair ^a   Persons, Derek A ^a   Riberdy, Janice M ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

FOXP3; ; Human T cell development; ; In vivo selection; IPEX; ; Non myeloablative transplantation; ; Regulatory T cell;

Indexed keywords

ALBUMIN; ALEMTUZUMAB; CD19 ANTIGEN; CYCLOSPORIN A; FLUDARABINE; HEMOGLOBIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; MELPHALAN; PALIFERMIN; PREDNISONE; RITUXIMAB; THIOTEPA; TRANSCRIPTION FACTOR FOXP3;

ALBUMIN BLOOD LEVEL; ARTICLE; BLOOD TRANSFUSION; BONE MARROW TRANSPLANTATION; CASE REPORT; CD3+ T LYMPHOCYTE; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHILD DEATH; CLOSTRIDIUM DIFFICILE INFECTION; COOMBS TEST; DEHYDRATION; DIARRHEA; DNA BINDING; DRUG EFFICACY; EOSINOPHILIA; FAILURE TO THRIVE; HEMOGLOBIN BLOOD LEVEL; HEMOLYTIC ANEMIA; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; INFANT; IPEX SYNDROME; MALE; MISSENSE MUTATION; MUCOSA INFLAMMATION; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RASH; STAPHYLOCOCCAL BACTEREMIA; STAPHYLOCOCCUS AUREUS; T CELL DEPLETION; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, NEOPLASM; BONE MARROW TRANSPLANTATION; CELL SURVIVAL; FORKHEAD TRANSCRIPTION FACTORS; GENETIC DISEASES, X-LINKED; GRAFT ENHANCEMENT, IMMUNOLOGIC; GRAFT SURVIVAL; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; INFANT; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LYMPHOCYTE DEPLETION; MALE; MELPHALAN; POINT MUTATION; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY; THIOTEPA; THYMUS GLAND; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIDARABINE;

EID: 80054842040     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2011.07.005     Document Type: Article

References (27)

1. Allan S.E., Crome S.Q., Crellin N.K., Passerini L., Steiner T.S., Bacchetta R., Roncarolo M.G., Levings M.K. Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int. Immunol. 2007, 19:345-354.
2. Bacchetta R., Passerini L., Gambineri E., Dai M., Allan S.E., Perroni L., gna-Bricarelli F., Sartirana C., Matthes-Martin S., Lawitschka A., Azzari C., Ziegler S.F., Levings M.K., Roncarolo M.G. Defective regulatory and effector T cell functions in patients with FOXP3 mutations. J. Clin. Invest. 2006, 116:1713-1722.
3. Baecher-Allan C., Brown J.A., Freeman G.J., Hafler D.A. CD4+CD25high regulatory cells in human peripheral blood. J. Immunol. 2001, 167:1245-1253.
4. Baecher-Allan C., Wolf E., Hafler D.A. MHC class II expression identifies functionally distinct human regulatory T cells. J. Immunol. 2006, 176:4622-4631.
5. Booth N.J., McQuaid A.J., Sobande T., Kissane S., Agius E., Jackson S.E., Salmon M., Falciani F., Yong K., Rustin M.H., Akbar A.N., Vukmanovic-Stejic M. Different proliferative potential and migratory characteristics of human CD4+ regulatory T cells that express either CD45RA or CD45RO. J. Immunol. 2010, 184:4317-4326.
6. d'Hennezel E., Ben-Shoshan M., Ochs H.D., Torgerson T.R., Russell L.J., Lejtenyi C., Noya F.J., Jabado N., Mazer B., Piccirillo C.A. FOXP3 forkhead domain mutation and regulatory T cells in the IPEX syndrome. N. Engl. J. Med. 2009, 361:1710-1713.
7. Di N.S., Cecconi M., Passerini L., McMurchy A.N., Baron U., Turbachova I., Vignola S., Valencic E., Tommasini A., Junker A., Cazzola G., Olek S., Levings M.K., Perroni L., Roncarolo M.G., Bacchetta R. Wild-type FOXP3 is selectively active in CD4+CD25(hi) regulatory T cells of healthy female carriers of different FOXP3 mutations. Blood 2009, 114:4138-4141.
8. Dorsey M.J., Petrovic A., Morrow M.R., Dishaw L.J., Sleasman J.W. FOXP3 expression following bone marrow transplantation for IPEX syndrome after reduced-intensity conditioning. Immunol. Res. 2009, 44:179-184.
9. Hoffmann P., Eder R., Boeld T.J., Doser K., Piseshka B., Andreesen R., Edinger M. Only the CD45RA+subpopulation of CD4+CD25high T cells gives rise to homogeneous regulatory T-cell lines upon in vitro expansion. Blood 2006, 108:4260-4267.
10. Ito T., Hanabuchi S., Wang Y.H., Park W.R., Arima K., Bover L., Qin F.X., Gilliet M., Liu Y.J. Two functional subsets of FOXP3+ regulatory T cells in human thymus and periphery. Immunity 2008, 28:870-880.
11. Junge S., Kloeckener-Gruissem B., Zufferey R., Keisker A., Salgo B., Fauchere J.C., Scherer F., Shalaby T., Grotzer M., Siler U., Seger R., Gungor T. Correlation between recent thymic emigrants and CD31+ (PECAM-1) CD4+ T cells in normal individuals during aging and in lymphopenic children. Eur. J. Immunol. 2007, 37:3270-3280.
12. Kimmig S., Przybylski G.K., Schmidt C.A., Laurisch K., Mowes B., Radbruch A., Thiel A. Two subsets of naive T helper cells with distinct T cell receptor excision circle content in human adult peripheral blood. J. Exp. Med. 2002, 195:789-794.
13. Liu W., Putnam A.L., Xu-Yu Z., Szot G.L., Lee M.R., Zhu S., Gottlieb P.A., Kapranov P., Gingeras T.R., Fazekas de St G.B., Clayberger C., Soper D.M., Ziegler S.F., Bluestone J.A. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J. Exp. Med. 2006, 203:1701-1711.
14. Lucas K.G., Ungar D., Comito M., Bayerl M., Groh B. Submyeloablative cord blood transplantation corrects clinical defects seen in IPEX syndrome. Bone Marrow Transplant. 2007, 39:55-56.
15. Miyara M., Yoshioka Y., Kitoh A., Shima T., Wing K., Niwa A., Parizot C., Taflin C., Heike T., Valeyre D., Mathian A., Nakahata T., Yamaguchi T., Nomura T., Ono M., Amoura Z., Gorochov G., Sakaguchi S. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 2009, 30:899-911.
16. Morales-Tirado V., Wichlan D.G., Leimig T.E., Street S.E., Kasow K.A., Riberdy J.M. 1alpha,25-dihydroxyvitamin D3 (vitamin D3) catalyzes suppressive activity on human natural regulatory T cells, uniquely modulates cell cycle progression, and augments FOXP3. Clin. Immunol. 2011, 138:212-221.
17. Morgan M.E., van Bilsen J.H., Bakker A.M., Heemskerk B., Schilham M.W., Hartgers F.C., Elferink B.G., van der Z.L., de Vries R.R., Huizinga T.W., Ottenhoff T.H., Toes R.E. Expression of FOXP3 mRNA is not confined to CD4+CD25+ T regulatory cells in humans. Hum. Immunol. 2005, 66:13-20.
18. Rao A., Kamani N., Filipovich A., Lee S.M., Davies S.M., Dalal J., Shenoy S. Successful bone marrow transplantation for IPEX syndrome after reduced-intensity conditioning. Blood 2007, 109:383-385.
19. Roncador G., Brown P.J., Maestre L., Hue S., Martinez-Torrecuadrada J.L., Ling K.L., Pratap S., Toms C., Fox B.C., Cerundolo V., Powrie F., Banham A.H. Analysis of FOXP3 protein expression in human CD4+CD25+ regulatory T cells at the single-cell level. Eur. J. Immunol. 2005, 35:1681-1691.
20. Sakaguchi S., Miyara M., Costantino C.M., Hafler D.A. FOXP3+ regulatory T cells in the human immune system. Nat. Rev. Immunol. 2010, 10:490-500.
21. Seddiki N., Santner-Nanan B., Martinson J., Zaunders J., Sasson S., Landay A., Solomon M., Selby W., Alexander S.I., Nanan R., Kelleher A., Fazekas de St G.B. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J. Exp. Med. 2006, 203:1693-1700.
22. Seidel M.G., Fritsch G., Lion T., Jurgens B., Heitger A., Bacchetta R., Lawitschka A., Peters C., Gadner H., Matthes-Martin S. Selective engraftment of donor CD4+25high FOXP3-positive T cells in IPEX syndrome after nonmyeloablative hematopoietic stem cell transplantation. Blood 2009, 113:5689-5691.
23. Sportes C., Hakim F.T., Memon S.A., Zhang H., Chua K.S., Brown M.R., Fleisher T.A., Krumlauf M.C., Babb R.R., Chow C.K., Fry T.J., Engels J., Buffet R., Morre M., Amato R.J., Venzon D.J., Korngold R., Pecora A., Gress R.E., Mackall C.L. Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets. J. Exp. Med. 2008, 205:1701-1714.
24. Vukmanovic-Stejic M., Zhang Y., Cook J.E., Fletcher J.M., McQuaid A., Masters J.E., Rustin M.H., Taams L.S., Beverley P.C., Macallan D.C., Akbar A.N. Human CD4+ CD25hi Foxp3+ regulatory T cells are derived by rapid turnover of memory populations in vivo. J. Clin. Invest. 2006, 116:2423-2433.
25. Walker M.R., Kasprowicz D.J., Gersuk V.H., Benard A., Van L.M., Buckner J.H., Ziegler S.F. Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+. J. Clin. Invest. 2003, 112:1437-1443.
26. Zhan H., Sinclair J., Adams S., Cale C.M., Murch S., Perroni L., Davies G., Amrolia P., Qasim W. Immune reconstitution and recovery of FOXP3 (forkhead box P3)-expressing T cells after transplantation for IPEX (immune dysregulation, polyendocrinopathy, enteropathy, X-linked) syndrome. Pediatrics 2008, 121:e998-e1002.
27. Ziegler S.F. FOXP3: of mice and men. Annu. Rev. Immunol. 2006, 24:209-226.